With the approval of drugs like Nivolumab and Pembrolizumab patients are already feeling the impact of cancer immunotherapy. Still, with each step forward researchers are becoming increasingly aware of the complexity and unique challenges that come with each individual’s disease. Given that not all patients respond to existing treatments, there is an enormous need to start looking at the next generation of immunotherapy solutions.
At Cambridge Healthtech Institute's Inaugural ImPACT: Immunotherapy Progress and Clinical Treatments, being held December 5-7, 2017 in San Diego, four cutting-edge conferences will showcase what’s coming next in immunotherapy.
Manufacturing Chimeric Antigen Receptor T Cells for Early Phase Clinical Trials
David F. Stroncek, M.D.
Chief, Cell Therapy Section, Transfusion Medicine, NIH Clinical Center
Evolution of Cancer Immunotherapy
Ramy Ibrahim, M.D.
VP, Clinical Development, Parker Institute for Cancer Immunotherapy